Address of Corresponding Author

Dement Geriatr Cogn Disord 2006;21:88-96 (DOI: 10.1159/000090224)

  Key Words

• Omega-3 fatty acids
• Treatment of dementia
• Alzheimer's disease
• Cognitive function in normal aging

  Abstract

We systematically reviewed the published literature on the effects of omega-3 fatty acids on measures of cognitive function in normal aging, incidence and treatment of dementia. Computerized databases were searched for published literature to identify potentially relevant studies with the intent to conduct a meta-analysis. We screened 5,865 titles, reviewed 497 studies of which 49 underwent a detailed review, and found 5 studies that pertained to our objectives. We included controlled clinical trials and observational studies, including prospective cohort, case-control, and case series designs; we excluded case reports. We had no language restrictions. We abstracted data on the effects of omega-3 fatty acids and on study design, relevant outcomes, study population, source, type, amount, and duration of omega-3 fatty acid consumption, and parameters of methodological quality. A single cohort study has assessed the effects of omega-3 fatty acids on cognitive function with normal aging and found no association for fish or total omega-3 consumption. In four studies that assessed the effects of omega-3 fatty acids on incidence and treatment of dementia, a trend in favor of omega-3 fatty acids (fish and total omega-3 consumption) toward reducing risk of dementia and improving cognitive function was reported. The available data are insufficient to draw strong conclusions about the effects of omega-3 fatty acids on cognitive function in normal aging or on the incidence or treatment of dementia. However, limited evidence suggests a possible association between omega-3 fatty acids and reduced risk of dementia.

Copyright © 2006 S. Karger AG, Basel

  References

1.

U.S. General Accounting Office: Alzheimer's Disease: Estimates of Prevalence in the United States (GAO/HEHS-98-16, 1-45). Washington, U.S. General Accounting Office, 1998.

2.

Hebert LE, Beckett LA, Scherr PA, Evans DA: Annual incidence of Alzheimer disease in the United States projected to the years 2000 to 2050. Alz Dis Assoc Disord 2001;4:169-173.

3.

Haan MN, Wallace R: Can dementia be prevented? Brain aging in a population-based context. Annu Rev Pub Health 2004;25:1-24.

4.

Hashimoto M, Hossain S, Shimada T, Sugioka K, Yamasaki H, Fujii Y, Ishibashi Y, Oka J, Shido O: Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J Neurochem 2002;81:1084-1091.

5.

Favrelere S, Stadelmann-Ingrand S, Huguet F, De Javel D, Piriou A, Tallineau C, Durand G: Age-related changes in ethanolamine glycerophospholipid fatty acid levels in rat frontal cortex and hippocampus. Neurobiol Aging 2000;21:653-660.

6.

Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem N Jr, Ashe KH, Frautschy SA, Cole GM: Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004;43:633-664.

7.

Cooper JL: Dietary lipids in the aetiology of Alzheimer's disease: implications for therapy. Drugs Aging 2003;20:399-418.

8.

Friedland R: Fish consumption and the risk of Alzheimer disease: is it time to make dietary recommendations? Arch Neurol 2003;60:923-924.

9.

http://qualitycounts.com/fpfattyacids.html. Accessed February 10, 2005.

10.

http://www.discount-vitamins-herbs.net/health-news27.htm. Accessed February 10, 2005.

11.

Weil M, Bressler J, Parsons P, Bolla K, Glass T, Schwartz B: Blood mercury levels and neurobehavioral function. JAMA 2005;293:1875-1882.

12.

MacLean CH, Issa AM, Newberry SJ, Mojica WA, Morton SC, Garland RH, Hilton LG, Traina SB, Shekelle PG: Effects of Omega-3 Fatty Acids on Cognitive Function with Aging, Dementia, and Neurological Diseases. Evidence Report/Technology Assessment No. 114 (Prepared by the Southern California Evidence-Based Practice Center, under contract No. 290-02-0003). Publication No. 05-E011-2. Rockville, Agency for Healthcare Research and Quality, February 2005.

13.

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.

14.

Downs S, Black N: The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377-384.

15.

Saunders L, Soomro G, Buckingham J, Jamtvedt G, Raina P: Assessing the methodological quality of nonrandomized intervention studies. West J Nurs Res 2003;25:223-237.

16.

Kalmijn S, Feskens EJ, Launer LJ, Kromhout D: Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol 1997;145:33-41.

17.

Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF, Renaud S: Fish, meat, and risk of dementia: cohort study. BMJ 2002;325:932-933.

18.

Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, Aggarwal N, Schneider J: Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003;60:940-946.

19.

Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM: Dietary fat intake and the risk of incident dementia in the Rotterdam study. Ann Neurol 1997;42:776-782.

20.

Terano T, Fujishiro S, Ban T, Yamamoto K, Tanaka T, Noguchi Y, Tamura Y, Yazawa K, Hirayama T: Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases. Lipids 1999;34(suppl):S345-S346.

21.

Willet W: Overview of nutritional epidemiology; in Willet W (ed): Nutritional Epidemiology, ed 2. New York, Oxford University Press, 1998, pp 3-17.

22.

Grimes DA, Schulz KF: Cohort studies: marching towards outcomes. Lancet 2002;359:341-345.

23.

Grimes DA, Schulz KF: Bias and causal associations in observational research. Lancet 2002;359:248-252.

  Author Contacts

Amalia M. Issa, MPH, PhD
RAND Corporation Division of Health
1776 Main Street
Santa Monica, CA 90401 (USA)
E-Mail aissa1@ucla.edu

  Article Information

The views expressed in this article are those of the authors and do not necessarily reflect those of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Accepted after revision: September 7, 2005
Published online: December 9, 2005
Number of Print Pages : 9
Number of Figures : 1, Number of Tables : 5, Number of References : 23

  Publication Details

Dementia and Geriatric Cognitive Disorders

Vol. 21, No. 2, Year 2006 (Cover Date: January 2006)

Journal Editor: Chan-Palay, V. (New York, N.Y.)
ISSN: 1420-8008 (print), 1421-9824 (Online)

For additional information: http://www.karger.com/DEM

  Drug Dosage / Copyright

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.